Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol

Leukemia Research

Volumn 26, Issue 3, 2002, Pages 271-280

  Semenov, Igor ^a   Akyuz, Canan ^a,b   Roginskaya, Vera ^a   Chauhan, Dharminder ^c   Corey, Seth J ^a,d  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Flavopiridol; Kinase; Myeloma; Signal transduction therapeutics

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PD 173; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOMA CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ADP-RIBOSYL CYCLASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; NAD+ NUCLEOSIDASE; PHOSPHOTYROSINE; PIPERIDINES; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 0036138680     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00103-5     Document Type: Article

References (29)

1. Advances in therapy of multiple myeloma: lessons from acute leukemia
2. The treatment of multiple myeloma
3. Ten-year survival and prognostic factors in multiple myeloma
4. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
5. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
6. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
7. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy
8. Thalidomide-a revival story
9. Antitumor activity of thalidomide in refractory multiple myeloma
10. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines
11. Multiple myeloma: increasing evidence for a multistep transformation process
12. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
13. Preclinical and clinical development of cyclin-dependent kinase modulators
14. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
15. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
16. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
17. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
18. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
19. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
20. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
21. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases
22. Isolation and characterization of human multiple myeloma cell enriched populations
23. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
24. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
25. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
26. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
27. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study
28. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
29. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia